Multidisciplinary Management of Orbital Rhabdomyosarcoma

  • Winston W. HuhEmail author
  • Anita Mahajan
Part of the M.D. Anderson Solid Tumor Oncology Series book series (MDA, volume 6)


Rhabdomyosarcoma (RMS) is the most common orbital malignancy in childhood. Embryonal RMS and alveolar RMS are the two most common histologic subtypes of RMS, and embryonal RMS is the most common subtype of orbital RMS. The clinical presentation of orbital RMS depends on the tumor location in the orbit. Diagnosis is chiefly made through open biopsy, and complete initial tumor resection is uncommon because of the risk of ocular morbidity. The treatment of orbital RMS requires a coordinated effort by the disciplines of ophthalmology, pathology, pediatric oncology, and radiation oncology. Because of advances in the planning and administration of chemotherapy and radiation therapy, the outcome for patients with orbital RMS has improved; the 3-year failure-free survival rate is greater than 90%, and the 3-year overall survival rate is 100%. Continued improvements in therapy are being investigated in an effort to decrease the risk of treatment-related late effects, such as cataracts and facial asymmetry.


Proton Therapy Complete Tumor Resection Proton Beam Therapy Granulocytic Sarcoma Orbital Cellulitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Gurney JG, Young JL, Roffers SD, et al. Soft tissue sarcomas. In: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR, editors. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995. Bethesda, MD: National Cancer Institute SEER Program, 1999. NIH Pub. No. 99-4649.Google Scholar
  2. 2.
    Arndt CAS, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999;341:342–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Shields JA, Shields CL, Scartozzi R. Survey of 1264 patients with orbital tumors and simulating lesions. The 2002 Montgomery lecture, part 1. Ophthalmology 2004;111:997–1008.PubMedCrossRefGoogle Scholar
  4. 4.
    Sorensen PHB, Lynch JC, Qualman SJ, et al. PAX3–FKHR and PAX7–FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol 2002;20:2672–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Crist WM, Anderson JR, Meza JL, et al. Intergroup Rhabdomyosarcoma Study—IV: results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091–102.PubMedGoogle Scholar
  6. 6.
    Kodet R, Newton WA, Hamoudi AB, et al. Orbital rhabdomyosarcomas and related tumors in childhood: relationship of morphology to prognosis—an Intergroup Rhabdomyosarcoma Study. Med Pediatr Oncol 1997;29:51–60.PubMedCrossRefGoogle Scholar
  7. 7.
    Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first 2 decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001;23:215–20.PubMedCrossRefGoogle Scholar
  8. 8.
    Sohaib SA, Moseley I, Wright JE. Orbital rhabdomyosarcoma—the radiological characteristics. Clin Radiol 1998;53:357–62.PubMedCrossRefGoogle Scholar
  9. 9.
    Karcioglu ZA, Hadjistilianou D, Rozans M, et al. Orbital rhabdomyosarcoma. Cancer Control 2004;11:328–33.PubMedGoogle Scholar
  10. 10.
    Park K, van Rijn R, McHugh K. The role of radiology in pediatric soft tissue sarcomas. Cancer Imaging 2008;8:102–15.PubMedCrossRefGoogle Scholar
  11. 11.
    Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003;21:78–84.PubMedCrossRefGoogle Scholar
  12. 12.
    Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study—I. A final report. Cancer 1988;61:209–20.PubMedCrossRefGoogle Scholar
  13. 13.
    Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study—II. Cancer 1993;71:1904–22.PubMedCrossRefGoogle Scholar
  14. 14.
    Crist W, Gehan EA, Ragab AH, et al. The third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610–30.PubMedGoogle Scholar
  15. 15.
    Oberlin O, Rey A, Anderson J, et al. Treatment of orbital rhabdomyosarcomas: survival and late effects of treatment—results of an international workshop. J Clin Oncol 2001;19:197–204.PubMedGoogle Scholar
  16. 16.
    Punyko JA, Mertens AC, Gurney JG, et al. Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2005;44:643–53.PubMedCrossRefGoogle Scholar
  17. 17.
    Sung L, Anderson JR, Donaldson SS, et al. Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Eur J Cancer 2004;40:1878–85.PubMedCrossRefGoogle Scholar
  18. 18.
    Raney RB, Anderson JR, Kollath J, et al. Late effects of therapy in 94 patients with localized rhabdomyosarcoma of the orbit: report from the Intergroup Rhabdomyosarcoma Study—III, 1984–1991. Med Pediatr Oncol 2000;34:413–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Fiorillo A, Migliorati R, Vassallo P, et al. Radiation late effects in children treated for orbital rhabdomyosarcoma. Radiother Oncol 1998;53:143–8.CrossRefGoogle Scholar
  20. 20.
    Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol 2007;25:953–64.PubMedCrossRefGoogle Scholar
  21. 21.
    Timmermann B, Schuck A, Niggli F, et al. Spot-scanning proton therapy for malignant soft tissue tumors in childhood: first experiences at the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys 2007;67:497–504.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of PediatricsThe University of Texas M. D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of Radiation OncologyThe University of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations